Bridge to Life's HOPE System Shows Promise in Uterus and Intestine Transplants
Event summary
- Bridge to Life's VitaSmart™ HOPE System demonstrated efficacy and safety in human uterus and small intestine transplants, presented at the 2026 Annual Meeting of the American Transplant Congress.
- Studies showed HOPE improved preservation parameters and reduced ischemic injury markers compared to static cold storage and normothermic perfusion.
- Current FDA clearance for VitaSmart™ is limited to liver transplants; additional studies and regulatory review are required for uterus and intestine applications.
The big picture
Bridge to Life's VitaSmart™ HOPE System is expanding its potential applications beyond liver transplants, addressing critical preservation challenges in uterus and intestine transplants. The data suggests HOPE could significantly improve organ viability and reduce ischemic injury, potentially unlocking new markets for the company. This aligns with broader industry trends toward advanced perfusion technologies aimed at enhancing transplant outcomes.
What we're watching
- Market Expansion Potential
- Whether Bridge to Life can leverage these findings to enter new markets for uterus and intestine transplants, currently limited by preservation challenges.
- Regulatory Pathway
- The pace at which additional studies and regulatory reviews will advance the clinical application of HOPE in uterus and intestine transplants.
- Competitive Positioning
- How these results position Bridge to Life against competitors developing alternative organ preservation technologies.
Related topics